EcoDrugPlus

Prostaglandin E2 Receptor Ep2 Subtype-Like

Ensembl ID : ENSOKIG00005013537
Gene Symbol: LOC109900292
3 Cross references
164 Possible Orthologues:

Prostaglandin E2 Receptor Ep2 Subtype-Like

Ensembl ID : ENSOKIG00005038209
Gene Symbol: LOC109882855
3 Cross references
198 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype

Ensembl ID : ENSOKIG00005039345
Gene Symbol: LOC109896145
3 Cross references
196 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSOKIG00005048651
Gene Symbol: LOC109873683
3 Cross references
195 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSOKIG00005021072
Gene Symbol: LOC109882928
3 Cross references
196 Possible Orthologues:

Prostaglandin F Receptor

Ensembl ID : ENSOKIG00005002403
Gene Symbol: PTGFR
3 Cross references
195 Possible Orthologues:

Prostaglandin G/h Synthase 2

Ensembl ID : ENSOKIG00005010606
Gene Symbol: LOC109898162
3 Cross references
203 Possible Orthologues:

Prostaglandin G/h Synthase 2

Ensembl ID : ENSOKIG00005050251
Gene Symbol: LOC109871539
3 Cross references
156 Possible Orthologues:

Prostaglandin G/h Synthase 2-Like

Ensembl ID : ENSOKIG00005037367
Gene Symbol: LOC109874966
3 Cross references
156 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSOKIG00005047918
Gene Symbol: PTGIR
3 Cross references
181 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSOKIG00005010261
Gene Symbol: PTGIR
3 Cross references
181 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSOKIG00005022764
Gene Symbol: PTGS1
3 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).